

# 80715

# SHMT1 (D3B3J) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

### For Research Use Only. Not for Use in Diagnostic Procedures

<b>Applications:</b> W, IP	Reactivity: H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 50	<b>Source/Isotype:</b> Rabbit IgG	UniProt ID: #P34896	Entrez-Gene Id: 6470
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 $\mu$ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		SHMT1 (D3B3J) recognizes endogenous levels of total SHMT1 protein. This antibody does not cross-react with SHMT2 protein.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu187 of human SHMT1 protein.				
Background		Serine hydroxymethyltransferases 1 and 2 (SHMT1, SHMT2) are cytoplasmic and mitochondrial serine hydroxymethyltransferases, respectively (1,2). They catalyze the conversion of serine to glycine with the transfer of β-carbon from serine to tetrahydrofolate (THF) to form 5,10-methylene-THF (1,2). Research studies indicate that SHMT1 hemizygosity is associated with higher risk of intestinal cancer in mice of a certain genetic background (3). Suppression of SHMT2 was shown to block cell proliferation (4).				
Background References		<ol> <li>MacFarlane, A.J. et al. (2008) J Biol Chem 283, 25846-53.</li> <li>Hebbring, S.J. et al. (2012) J Neurochem 120, 881-90.</li> <li>Macfarlane, A.J. et al. (2011) Cancer Res 71, 2098-107.</li> <li>di Salvo, M.L. et al. (2013) Med Hypotheses 80, 633-6.</li> </ol>				
Species Reactivity		Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting IP: Immunoprecipitation				
6 B		Hallana an Managan Ba	D . 141 14 1			

### **Cross-Reactivity Key**

H: Human M: Mouse R: Rat Mk: Monkey

### **Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any

commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.